Stomach Cancer Trial, Recruiting NCT06961526 Sponsor: Tanta University Condition: Stomach Cancer
Back to Stomach Cancer

Stomach Cancer Trial, Recruiting

NCT06961526
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People with confirmed advanced liver cancer (hepatocellular carcinoma), diagnosed through two imaging scans or a liver biopsy, who are eligible for a combination treatment called atezolizumab-bevacizumab.
  • People whose liver is still functioning reasonably well — specifically, those rated as Child-Pugh A (a medical scoring system for liver health) if they have underlying liver scarring (cirrhosis).
  • People whose general physical health and ability to carry out daily activities is rated at 2 or below on a standard medical scale (called the ECOG performance status scale, where 0 means fully active and higher numbers mean more limited).
  • People who have no esophageal varices (enlarged veins in the food pipe) or only mild ones that are considered low-risk, confirmed by a pre-treatment camera examination of the digestive tract.

Who may not be able to join:

  • People whose liver function is severely reduced, rated as Child-Pugh class C.
  • People whose general physical health and activity level is rated above 2 on the standard medical scale.
  • People with blood vessel disorders or uncontrolled high blood pressure.
  • People with serious autoimmune conditions (where the immune system attacks the body).
  • People who are unlikely to attend follow-up appointments.
  • People who are pregnant or breastfeeding.
  • People who do not wish to take part in the study.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 28 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Rania M Elkafoury, MD, Tropical medicine and infectious diseases Department, Faculty of Medicine, Tanta University

Phone: +201004672358

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Tanta University
Registry
ClinicalTrials.gov
Start date
15 February 2025
Est. completion
1 July 2026

Where this trial is recruiting

🇪🇬 Egypt

Primary endpoints

esophagogastric varices progression rate; variceal band ligation in small varices without bleeding stigmata

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov